Research programme: anti-IL2 receptor antibody - Amgen
Alternative Names: MT-204Latest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator Micromet Inc
- Developer Amgen
- Class Antibodies
- Mechanism of Action Interleukin 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- No development reported Multiple sclerosis; Rheumatoid arthritis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Multiple-sclerosis in Germany (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in Germany (Parenteral)
- 07 Mar 2012 Micromet Inc has been acquired by Amgen